Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine - Wikidata - awgldk - TriplyDB

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

http://www.wikidata.org/entity/Q24649503

about

sameAs

Inhibition of phosphodiesterase 10A has differential effects on dopamine D1 and D2 receptor modulation of sensorimotor gating.Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications Stress history increases alcohol intake in relapse: relation to phosphodiesterase 10A.Patented PDE10A inhibitors: novel compounds since 2007.Leading compounds for the validation of animal models of psychopathology.Temporal and spatial regulation of cAMP signaling in disease: role of cyclic nucleotide phosphodiesterases.Phosphodiesterase 10 inhibitors in clinical development for CNS disorders.Disparate effects of pramipexole on locomotor activity and sensorimotor gating in Sprague-Dawley rats.Critical role of nitric oxide in the modulation of prepulse inhibition in Swiss mice.Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.Sensorimotor gating is disrupted by acute but not chronic systemic exposure to caffeine in mice.

P2860

Q28385659-982709E5-AB7D-43B1-8990-5A30F9630ED6 Q28386042-B1B88436-0A20-4C6B-9560-838E6BCE0A99 Q28396609-5C3CEB4F-6902-4E5A-84F3-955F00440FAF Q30449836-5B203804-7FC0-472C-B7D7-55688E1EA0EE Q37638739-E1FAF553-C822-41F5-AAB4-8398511043B4 Q38128733-A9BD9E70-1196-483E-A4F7-C0392611610C Q38205932-37521979-6329-493A-9F8E-17E188BCB55A Q39029199-14A8ECF5-F6C3-4A87-B22D-BDCB1922FF76 Q43587977-9056266A-F762-42D1-A552-E5E96BCF7170 Q46986165-B86F696B-E294-49E7-BDDD-3E6372D507EF Q48093702-8F4963FB-AE78-4998-85CF-A73BB72E3440 Q52649350-8451F80C-D547-4F0B-995C-DC6D6E81C20F

P2860

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

http://www.wikidata.org/entity/Q24649503

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@ast

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@en

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@nl

type

label

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@ast

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@en

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@nl

prefLabel

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@ast

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@en

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@nl

P1433

Q24649503-D7586E17-54E7-40F9-A775-ECB8DE2034B7

P1476

Q24649503-1F4503B3-FF15-4ADA-B722-D341A53C11F2

P2093

Q24649503-5126B84F-019F-4695-A136-47DCED4B4FC0

Q24649503-8777F615-2A07-4DCF-A68B-27219784E30C

Q24649503-9265B075-42D2-4F0E-82F2-760A3EB90D2C

Q24649503-B5B07BFF-E726-4C4B-97A6-5317EC18D609

Q24649503-C8F756DC-C37A-4076-B662-77132E0F7B0C

Q24649503-D0DDB2E9-0E48-4ED4-ACE6-49D1B95EE52B

P2860

Q24649503-02D9D9FB-853B-42B3-9E50-E5D8C88D675F

Q24649503-0B977A42-30D2-4702-BF80-84728B75B892

Q24649503-19925E2C-6D37-4D66-AB98-DE26601BE923

Q24649503-22FE7E9A-4800-4D5B-ACE3-10A599F94D58

Q24649503-2CDC1BB3-84E8-4E2E-8817-A7008B6DDB11

Q24649503-3A88D575-1F12-4DAE-92AB-0B1CEBA50320

Q24649503-424DC802-953D-4C71-945C-981FA9F72A38

Q24649503-4368708A-294C-4E75-8A60-9CA784E2BD6E

Q24649503-4C7D7C88-2C85-48EB-8C64-862BFD3DC004

Q24649503-4CB1D366-9AD0-497C-91F4-055881016BA9

P2888

Q24649503-DD4D8AA7-8B9D-4A7A-BA32-A6DD23A3A965

P304

Q24649503-210CD5DA-77AB-479C-A878-B18CEB8FED7C

P31

Q24649503-EE77F391-6915-4F21-8ABE-213BC0B95759

P356

Q24649503-2B5D43F0-B291-452E-8113-6483306DC217

P407

Q24649503-E52C8827-7FB9-4C41-B11C-AD256A85E0F5

P433

Q24649503-0EB2D2D3-B781-4A25-A4E0-9ACD062DD5AD

P478

Q24649503-FEE637E1-0AED-4FB9-B48B-8F423439D365

P577

Q24649503-B3DF0E01-A7C6-4BE6-AE55-D715C5B57C85

P5875

Q24649503-5E162AF1-DCCD-496A-BDA2-BADA97454797

P6179

Q24649503-18776BE7-F7DF-4BFE-826E-C2D16F41F6A4

P698

Q24649503-E37D5B18-B106-4FEB-B0C4-4833C3CA835D

P932

Q24649503-00CC5C4E-4D08-4E01-8C4C-AFD2CEE212E6

P356

S00213-008-1419-X

P1433

Psychopharmacology

P1476

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

@en

P2093

D E Marzan

http://www.w3.org/2001/XMLSchema#string

D Ko

http://www.w3.org/2001/XMLSchema#string

M Breier

http://www.w3.org/2001/XMLSchema#string

M Weber

http://www.w3.org/2001/XMLSchema#string

N R Swerdlow

http://www.w3.org/2001/XMLSchema#string

N Thangaraj

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A)

Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum

Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity.

Realistic expectations of prepulse inhibition in translational models for schizophrenia research.

Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits

The endophenotype concept in psychiatry: etymology and strategic intentions

Presidential Address, 1974. The more or less startling effects of weak prestimulation

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies

Repeated quinpirole treatment increases cAMP-dependent protein kinase activity and CREB phosphorylation in nucleus accumbens and reverses quinpirole-induced sensorimotor gating deficits in rats

P2888

s00213-008-1419-x

P304

723-35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00213-008-1419-X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

203

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23642199

http://www.w3.org/2001/XMLSchema#string

P6179

1008137220

http://www.w3.org/2001/XMLSchema#string

P698

19066855

http://www.w3.org/2001/XMLSchema#string

P932

2748940

http://www.w3.org/2001/XMLSchema#string